CXCL8-Binding L-Nucleic Acid for Selective Chemokine Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting CXCL8 often lack specificity, interfering with related chemokines and having limited efficacy due to rapid degradation and pharmacokinetic issues, necessitating the development of a nucleic acid molecule that selectively binds to CXCL8 with high affinity and inhibits its activity while minimizing interference with other ELR-positive chemokines.
Innovation Solution
A biostable L-nucleic acid molecule with a specific nucleotide sequence, such as 5′-GGAAGUACGUGGAAAGCCRA(XU)RAGUGUGUCCCG-3′, designed to bind CXCL8 with high affinity and inhibit CXCL8-stimulated chemotaxis, while minimizing interaction with chemokines like CXCL1, CXCL2, CXCL3, CXCL5, and CXCL7.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies targeting CXCL8 are used, then CXCL8 activity is inhibited, but related chemokines (CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7) are also interfered with due to lack of specificity
Solution Approach 1:
The nucleic acid molecule is designed with a specific nucleotide sequence (5′-GGAAGUACGUGGAAAGCCRA(XU)RAGUGUGUCCCG-3′) that creates local structural complementarity to CXCL8's binding interface. This local structural match enables selective binding to CXCL8 while avoiding interaction with related chemokines that lack the precise structural features required for high-affinity binding.
Solution Approach 2:
The nucleic acid molecule exhibits asymmetric structural features that complement the asymmetric binding interface of CXCL8. The specific arrangement of nucleotides creates an asymmetric binding surface that matches CXCL8's unique structural characteristics, thereby achieving high specificity without cross-reacting with symmetric or differently structured related chemokines.
2Reliability
If conventional therapies targeting CXCL8 are used, then CXCL8 activity is inhibited, but therapeutic efficacy is limited due to rapid degradation and pharmacokinetic issues
Solution Approach 1:
The invention changes the fundamental chemical parameters of the therapeutic agent by using an L-nucleic acid molecule instead of conventional small molecule drugs or antibodies. The L-nucleic acid structure provides enhanced stability against nucleases and other degrading enzymes, while the specific nucleotide sequence maintains high binding affinity to CXCL8, thereby improving both stability and therapeutic efficacy simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The L-nucleic acid molecule effectively inhibits CXCL8-mediated activities with picomolar range affinity, providing therapeutic potential for diseases involving CXCL8, while maintaining selectivity and stability, thus overcoming the limitations of existing treatments.
Implementation Method 1
designed to bind CXCL8 with high affinity and inhibit CXCL8-stimulated chemotaxis
Implementation Method 2
The L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GGAAGUACGUGGAAAGCCRA(XU)RAGUGUGUCCCG-3′
Data Source
AI summary
The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3′[SEQ. ID. NO: 27], wherein Xu is U or absent.